NCT03664635 - MB-CART20.1 Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

September 17, 2024

Study Completion Date

September 17, 2024

Conditions

Relapsed or Refractory B-cell Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaB-cell Lymphoma RefractoryB-cell Lymphoma Recurrent

Interventions

BIOLOGICAL

MB-CART20.1

MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL

Trial Locations (2)

50937

University Hospital of Cologne - Clinic for Internal Medicine I, Cologne

Unknown

Universitätsklikum Leipzig, AöR, Leipzig